Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose PK and safety study of BI 1584862 in healthy Japanese males
jRCT2071230088Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in geographic atrophy (GA) comparing BI 1584862 single oral dose with Placebo single oral dose (2 arms). Primary endpoint: Treatment-emergent drug-related adverse events. Started Dec 2023; status: completed.
02
Drugs
BI 1584862
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on jRCT2071230088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230088.